Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...